Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

ASCO 2019 /
KEYNOTE-062 study: Pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers

31st May - 4th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.06.19
Views: 585
Rating:

Dr Josep Tabernero - Vall d’Hebron Barcelona University Hospital, Barcelona, Spain

Dr Josep Tabernero talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about the use of immunotherapy agent pembrolizumab as treatment for advanced gastroesophageal junction and gastric cancers.

He explains that this study had three arms: single agent pembrolizumab, pembrolizumab and chemotherapy, or chemotherapy plus placebo.

Dr Tabernero reports that the comparison of pembrolizumab and chemotherapy met the primary endpoint of non-inferiority for overall survival, favouring pembrolizumab.

Watch the press conference here.

Watch Dr. Schilsky's comment here

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation